Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
RESEARCH TOOLSreports
Top Page
Biodexa Pharmaceuticals
(NASDAQ:BDRX)
45Neutral
Biodexa Pharmaceuticals (BDRX) vs. S&P 500 (SPY)
Market Cap
$996.20K
Dividend YieldN/A
Average Volume (3M)2.38M
Price to Earnings (P/E)―
Beta (1Y)2.38
Revenue Growth-83.72%
EPS Growth99.56%
CountryUS
Employees21
SectorHealthcare
Sector Strength66
IndustryBiotechnology
Share Statistics
EPS (TTM)-49.74
Shares Outstanding668,592
10 Day Avg. Volume4,061,431
30 Day Avg. Volume2,383,267
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.57
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside1108.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Biodexa Pharmaceuticals Business Overview & Revenue Model
Company DescriptionBiodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
How the Company Makes MoneyBiodexa Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products and drug delivery technologies. The company's revenue model is primarily based on sales of its proprietary drug formulations and delivery systems to healthcare providers, pharmaceutical companies, and distributors. Additionally, Biodexa may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to further develop and market its technologies, which can provide additional revenue streams through milestone payments, royalties, or co-development deals. Key factors contributing to its earnings include successful clinical trials, regulatory approvals, and the ability to effectively market its products to target demographics.
Biodexa Pharmaceuticals Financial Statement Overview
Summary
Biodexa Pharmaceuticals demonstrates weak financial performance with declining revenues, negative profitability margins, and persistent cash flow issues. Despite a favorable debt-to-equity ratio, the overall financial health is compromised by ongoing losses and inefficiencies in generating profits.Income Statement
Biodexa Pharmaceuticals shows a decreasing revenue trend over the years with a significant decline from $674,000 in 2019 to $381,000 in 2023. The gross profit margin is negative, indicating cost of goods sold surpasses revenue. Net profit margin is also negative, representing ongoing unprofitability. Despite some improvement in EBITDA margin, overall financial health remains weak due to persistent losses.45
Neutral
Balance Sheet
The debt-to-equity ratio is favorable, with relatively low leverage indicating the company relies more on equity than debt for financing. The equity ratio is stable, reflecting moderate financial stability. However, consistent negative net income impacts the return on equity, suggesting inefficiencies in generating profits from shareholders' equity.60
Neutral
Cash Flow
Operating cash flow remains negative, signaling challenges in generating cash from operations. Free cash flow shows a slight improvement but remains negative, indicating ongoing cash burn. The operating cash flow to net income ratio suggests that cash generation issues are consistent with net losses. Financing activities are primarily funding operations, as seen from significant cash inflows.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 124.50K | 381.00K | 699.00K | 578.00K | 343.00K | 674.00K | Gross Profit |
| -5.44M | -3.69M | -4.41M | -4.08M | -5.72M | -7.17M | EBIT |
| -9.17M | -8.01M | -8.93M | -7.00M | -10.67M | -11.32M | EBITDA |
| -7.59M | -7.16M | -7.39M | -5.66M | -22.22M | -9.54M | Net Income Common Stockholders |
| -8.57M | -7.08M | -7.66M | -5.46M | -22.19M | -9.14M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.97M | 5.97M | 2.84M | 10.06M | 7.55M | 10.93M | Total Assets |
| 10.54M | 10.54M | 5.53M | 12.91M | 9.82M | 30.89M | Total Debt |
| 464.00K | 464.00K | 624.00K | 766.00K | 260.00K | 6.08M | Net Debt |
| -5.51M | -5.51M | -2.21M | -9.29M | -7.29M | -4.85M | Total Liabilities |
| 5.86M | 5.86M | 2.36M | 2.46M | 3.10M | 11.34M | Stockholders Equity |
| 4.68M | 4.68M | 3.16M | 10.45M | 6.72M | 19.56M |
| Cash Flow | Free Cash Flow | ||||
| -9.26M | -7.09M | -7.11M | -6.33M | -9.51M | -6.81M | Operating Cash Flow |
| -9.22M | -6.83M | -7.05M | -6.01M | -9.30M | -6.49M | Investing Cash Flow |
| -1.18M | -265.00K | -220.00K | -278.00K | 2.57M | -3.81M | Financing Cash Flow |
| 10.61M | 10.23M | 47.00K | 8.80M | 3.08M | 18.73M |
Biodexa Pharmaceuticals Technical Analysis
Negative
1.49
Price Trends
3.51
Negative
4.12
Negative
9.39
Negative
Market Momentum
-0.57
Positive
26.68
Positive
5.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Negative. The current price of 1.49 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 3.51, and below the 200-day MA of 9.39, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 26.68 is Positive, neither overbought nor oversold. The STOCH value of 5.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDRX.
Biodexa Pharmaceuticals Risk Analysis
Biodexa Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Biodexa Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biodexa Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.88B | 0.82 | -52.97% | 2.48% | 20.92% | 1.17% | |
48 Neutral | $30.37M | ― | 210.50% | ― | 1.63% | 6.97% | |
45 Neutral | $996.20K | ― | -96.61% | ― | -83.72% | 99.56% | |
44 Neutral | $17.73M | ― | 291.66% | ― | ― | ― | |
39 Underperform | $248.44M | ― | -16.20% | ― | 498.72% | 49.92% |
* Healthcare Sector Average
Performance Comparison
BDRX
Biodexa Pharmaceuticals
1.49
-39.01
-96.32%
XOMA
Xoma
21.13
-2.92
-12.14%
EGRX
Eagle Pharmaceuticals
1.00
-4.24
-80.92%
MRNS
Marinus
0.55
-8.49
-93.92%
AKTX
Akari Therapeutics
1.30
-0.56
-30.11%
FENC
Fennec Pharmaceuticals
6.47
-4.65
-41.82%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.